NCT05792462View on ClinicalTrials.gov

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
NMO Spectrum Disorder
Interventions
DRUG

Baricitinib

Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.

Trial Locations (1)

300052

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
collaborator

Tang-Du Hospital

OTHER

collaborator

The Second Hospital of Shandong University

OTHER

lead

Tianjin Medical University General Hospital

OTHER